Motivation to Consent and Adhere to the FORT Randomized Controlled Trial.
breast and gynecological cancer
clinical trial
cognitive-existential approach
fear of cancer recurrence
group intervention
interpretive description
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
17 04 2022
17 04 2022
Historique:
received:
24
03
2022
revised:
11
04
2022
accepted:
15
04
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
The aim of this qualitative study was to identify the motivational factors that influence cancer survivors to participate and adhere to the fear of cancer recurrence (FCR) FORT randomized controlled trial (RCT). Fifteen women diagnosed with breast and gynecological cancer who took part in the FORT RCT were interviewed about their experience to consent and adhere to the trial. The transcribed interviews were content analyzed within a relational autonomy framework. The analysis revealed that the participants' motivation to consent and adhere to the FORT RCT was structured around thirteen subthemes grouped into four overarching themes: (1) Personal Influential Factors; (2) Societal Motivations; (3) Structural Influences; and (4) Gains in Emotional Support. The unique structures of the trial such as the group format, the friendships formed with other participants in their group and with the group leaders, and the right timing of the trial within their cancer survivorship trajectory all contributed to their motivation to consent and adhere to the FORT RCT. While their initial motivation to participate was mostly altruistic, it was their personal gains obtained over the course of the trial that contributed to their adherence. Potential gains in emotional and social support from psycho-oncology trials should be capitalized when approaching future participants as a mean to improve on motivations to consent and adhere.
Identifiants
pubmed: 35448206
pii: curroncol29040232
doi: 10.3390/curroncol29040232
pmc: PMC9025660
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2848-2863Références
J Cancer Surviv. 2014 Sep;8(3):485-96
pubmed: 24756313
Support Care Cancer. 2015 Apr;23(4):1169-96
pubmed: 25591627
Patient Educ Couns. 2018 Apr;101(4):711-716
pubmed: 29191626
Oncol Nurs Forum. 2010 Nov;37(6):E387-99
pubmed: 21059572
Eur J Cancer Care (Engl). 2003 Jun;12(2):114-22
pubmed: 12787008
Child Adolesc Psychiatry Ment Health. 2019 Jan 10;13:2
pubmed: 30647769
Psychooncology. 2007 Mar;16(3):181-8
pubmed: 16856147
J Cancer Surviv. 2013 Sep;7(3):300-22
pubmed: 23475398
J Natl Cancer Inst. 2021 Mar 1;113(3):244-257
pubmed: 33022716
Support Care Cancer. 2016 Aug;24(8):3265-8
pubmed: 27169703
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
Trials. 2018 Mar 27;19(1):205
pubmed: 29587805
BMC Cancer. 2016 Apr 25;16:291
pubmed: 27112319
Psychooncology. 2018 Nov;27(11):2546-2558
pubmed: 29744965
Support Care Cancer. 2016 Feb;24(2):849-856
pubmed: 26223321
J Clin Oncol. 2019 Nov 1;37(31):2899-2915
pubmed: 31532725
Oncol Nurs Forum. 2018 Nov 1;45(6):703-712
pubmed: 30339145
J Cancer Surviv. 2015 Sep;9(3):481-91
pubmed: 25603948
J Clin Nurs. 2010 Jan;19(1-2):227-33
pubmed: 20500260
J Womens Health (Larchmt). 2018 Mar;27(3):258-270
pubmed: 29148879
Soc Sci Med. 2006 May;62(10):2565-76
pubmed: 16303220
Support Care Cancer. 2017 May;25(5):1373-1375
pubmed: 28150044
Psychosom Med. 1979 May;41(3):209-18
pubmed: 472086
Cancer Nurs. 2010 Mar-Apr;33(2):E9-16
pubmed: 20142745
Res Nurs Health. 1997 Apr;20(2):169-77
pubmed: 9100747
Br J Psychiatry. 2002 Mar;180:205-9
pubmed: 11872511
Contemp Clin Trials Commun. 2016 Mar 02;3:23-31
pubmed: 29736453
Can J Nurs Res. 2009 Mar;41(1):292-319
pubmed: 19485058
Trials. 2018 Jan 29;19(1):76
pubmed: 29378618
Trials. 2018 Sep 29;19(1):528
pubmed: 30268150
Support Care Cancer. 2009 Mar;17(3):241-51
pubmed: 18414902
JAMA Oncol. 2022 May 1;8(5):775-778
pubmed: 35323841